So up guys, Derek, I want to play tomorrow dates.com.

Today we're going to be talking about S4, also known as Anderine.

This is going to be the most comprehensive YouTube video and post on the entire internet about S4.

I promise you that.

So stick around if you want to hear everything from preclinical data, you know, efficacy, side effects, what you can

expect, how it works at the androgen receptor level, pharmacodynamics, pharmacokinetics,

et cetera. Let's get into it. So S4, also known as Anderine, is an abandoned selective

androgen receptor modulator SARM that was intended mainly for the treatment

of benign prostatic hypertrophy. So this is not to be confused with S-40503 because, you know,

everyone sees the S-dash-4 and they think it's the same thing. It's definitely not. S-4 is a SARM originally developed by GTX,

Inc, with the intention of treating a variety of degenerative musculoskeletal diseases and benign

prostate hypertrophy. It was also being evaluated for its potential therapeutic applications

in males and females for modulation of fertility,

erythropolysis, osteoporosis, sexual libido, and in men with or at high risk of prostate

cancer. It's orally bioavailable, no injections needed, non-seroidal, and has tissue-selective

anabolic effects in muscle and bone while sparing other

endogenic effects that come from anabolic endogenic steroids now when i say sparing i mean

relative that's not necessarily absent of those effects testosterone and dhc are the main

endogenous androgens produced in the body that fulfill basic physiological functions in men.

These are essential for male development, as well as the maintenance of male secondary characteristics.

The ability to build muscle and maintain bone mineral density among several other key processes are facilitated via these hormones, but they are inherently

flawed by their lack of tissue selectivity. DHC is several fold more endogenic than testosterone

...